2024
High p16INK4A expression in glioblastoma is associated with senescence phenotype and better prognosis
Park S, Roh T, Tanaka Y, Kim Y, Park S, Kim T, Eom S, Park T, Park I, Kim S, Kim J. High p16INK4A expression in glioblastoma is associated with senescence phenotype and better prognosis. Neoplasia 2024, 60: 101116. PMID: 39724755, PMCID: PMC11729681, DOI: 10.1016/j.neo.2024.101116.Peer-Reviewed Original ResearchConceptsP16<sup>INK4a</sup> expressionImmune cell infiltrationTumor cellsCell infiltrationImmunologically active tumor microenvironmentInfiltration of T cellsActive tumor microenvironmentTERT promoter mutationsExtended overall survivalIsocitrate dehydrogenase (IDH)-wildtypeSecretion of chemokinesSenescent phenotypeMalignant brain tumorsIn vitro studiesEGFR amplificationOverall survivalTumor microenvironmentCDKN2A/2B deletionT cellsPrognostic markerImprove prognosisP16INK4A expressionPromoter mutationsTumorBrain tumors
2022
Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma
Coy S, Wang S, Stopka S, Lin J, Yapp C, Ritch C, Salhi L, Baker G, Rashid R, Baquer G, Regan M, Khadka P, Cole K, Hwang J, Wen P, Bandopadhayay P, Santi M, De Raedt T, Ligon K, Agar N, Sorger P, Touat M, Santagata S. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. Nature Communications 2022, 13: 4814. PMID: 35973991, PMCID: PMC9381513, DOI: 10.1038/s41467-022-32430-w.Peer-Reviewed Original ResearchConceptsPediatric high-grade gliomasHigh-grade gliomasDiffuse midline gliomaH3K27M-mutant diffuse midline gliomaAstrocyte-like differentiationPoor outcomeInflammatory microenvironmentClinical significanceMidline gliomaTherapeutic targetingMyeloid cellsPurinergic signalingImmune adaptationEGFR amplificationTumor cellsGliomasExtracellular purinergicPurinergicGlioblastomaCD39CD73Functional stateMicroenvironmentMicrogliaCells
2021
B2M overexpression correlates with malignancy and immune signatures in human gliomas
Zhang H, Cui B, Zhou Y, Wang X, Wu W, Wang Z, Dai Z, Cheng Q, Yang K. B2M overexpression correlates with malignancy and immune signatures in human gliomas. Scientific Reports 2021, 11: 5045. PMID: 33658560, PMCID: PMC7930032, DOI: 10.1038/s41598-021-84465-6.Peer-Reviewed Original ResearchMeSH Keywordsbeta 2-MicroglobulinBiomarkers, TumorBrain NeoplasmsCarcinogenesisCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticGenomicsGliomaHumansImmune Checkpoint ProteinsImmune ToleranceImmunotherapyIsocitrate DehydrogenaseKaplan-Meier EstimateMutationPrognosisPTEN PhosphohydrolaseTumor MicroenvironmentConceptsB2M expressionImmune signaturesM expressionB2MAssociated with immune checkpoint moleculesAssociated with PTEN deletionSuppress anti-tumor immunityAnti-tumor immunityImmune checkpoint moleculesImmunotherapy of gliomaLimited treatment strategiesStromal cell typesCheckpoint moleculesEGFR amplificationClinical characteristicsPTEN deletionPatient prognosisTumor progressionTreatment strategiesGenomic profilingInflammatory activityImmunotherapySomatic mutationsCGGA databasesGlioma
2016
Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition
Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh W, Zhu J, McBride R, Cordon-Cardo C, Solit D, Sfakianos J, Galsky M. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. European Urology 2016, 70: 771-775. PMID: 27178450, PMCID: PMC5489411, DOI: 10.1016/j.eururo.2016.04.037.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntineoplastic AgentsCetuximabColonic NeoplasmsDrug Resistance, NeoplasmErbB ReceptorsExome SequencingFemaleHumansMaleMitogen-Activated Protein KinasesMutationNeoplasm MetastasisNeoplasm StagingPharmacogenomic TestingProto-Oncogene Proteins p21(ras)Signal TransductionUrinary Bladder NeoplasmsConceptsMetastatic urachal cancerUrachal cancerTargeted exome sequencingUrachal carcinomaEGFR amplificationColorectal cancerMitogen-activated protein kinaseParaffin-embedded tumor specimensMetastatic urachal carcinomaMonoclonal antibodiesSingle-agent cetuximabTreated with cetuximabEpidermal growth factor inhibitionEpidermal growth factor receptorLimited treatment optionsWild-type KRASPrimary tumor tissuesGrowth factor inhibitionGrowth factor receptorWhole-exome sequencingEnteric adenocarcinomaCetuximab sensitivitySystemic therapyTumor specimensAggressive malignancy
2006
EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial
Miller V, Zakowski M, Riely G, Pao W, Ladanyi M, Tsao A, Sandler A, Herbst R, Kris M, Johnson D. EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. Journal Of Clinical Oncology 2006, 24: 7003-7003. DOI: 10.1200/jco.2006.24.18_suppl.7003.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply